[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Gupta MD, Chakrabarti N, Agrawal P, Narurkar S: Angiosarcoma of the scalp. Indian J Plast Surg; 2009 Jan-Jun;42(1):118-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiosarcoma of the scalp.
  • Angiosarcoma is a relatively rare soft tissue tumour.
  • The treatment depends on the extent of the disease.
  • Radiotherapy and chemotherapy are advocated in the recurrent or extensive lesions with regional or distant metastasis.
  • Initially thought to be a pyogenic granuloma, on excisional biopsy it was diagnosed as angiosarcoma with microscopic involvement of the margins.
  • The patient was not given postoperative radiotherapy or chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):983-96 [16006792.001]
  • [Cites] Arch Dermatol. 1980 Jun;116(6):683-6 [7189653.001]
  • [Cites] Cancer. 1981 Oct 15;48(8):1907-21 [7197190.001]
  • [Cites] Am J Surg. 1994 Nov;168(5):451-4 [7977971.001]
  • [Cites] J Cancer Res Clin Oncol. 2001;127(6):396-9 [11414200.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2000 Sep;14(5):412-5 [11305388.001]
  • [Cites] Jpn J Clin Oncol. 2003 Apr;33(4):198-201 [12810835.001]
  • [Cites] Cancer. 1987 Mar 1;59(5):1046-57 [3815265.001]
  • [Cites] Cancer. 1995 Jul 15;76(2):319-27 [8625109.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1997 Nov;106(11):943-51 [9373085.001]
  • (PMID = 19881033.001).
  • [ISSN] 1998-376X
  • [Journal-full-title] Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India
  • [ISO-abbreviation] Indian J Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2772288
  •  go-up   go-down


2. Ryu DY, Hwang SY, Lee DW, Kim TO, Park DY, Kim GH, Heo J, Kang DH, Song GA, Cho M: [A case of primary angiosarcoma of small intestine presenting as recurrent gastrointestinal bleeding]. Korean J Gastroenterol; 2005 Nov;46(5):404-8
MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary angiosarcoma of small intestine presenting as recurrent gastrointestinal bleeding].
  • Angiosarcoma is a rare malignant tumor which occurs frequently in the skin and soft subcutis.
  • Surgery, chemotherapy and radiotherapy are the mainstay of treatment.
  • We report a case of primary angiosarcoma of the small intestine presenting as recurrent gastrointestinal bleeding.
  • A 54-year-old man was admitted with recurrent gastrointestinal bleeding.
  • The ileal mass was diagnosed as angiosarcoma on immunohistochemical stain.
  • He received 3 cycles of chemotherapy, but died 5 months after the diagnosis.
  • [MeSH-major] Gastrointestinal Hemorrhage / etiology. Hemangiosarcoma / diagnosis. Intestinal Neoplasms / diagnosis. Intestine, Small

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16301855.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


3. Chen W, Shih CS, Wang YT, Tseng GC, Hsu WH: Angiosarcoma with pulmonary metastasis presenting with spontaneous bilateral pneumothorax in an elderly man. J Formos Med Assoc; 2006 Mar;105(3):238-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiosarcoma with pulmonary metastasis presenting with spontaneous bilateral pneumothorax in an elderly man.
  • Cutaneous angiosarcoma is a rare and invasive endothelial-derived sarcoma that occurs most frequently in the scalp and facial skin of elderly men.
  • We report a case of angiosarcoma of the scalp with cystic metastasis to the lung in a 63-year-old man, presenting as recurrent bilateral spontaneous pneumothorax.
  • Two months later, bilateral pneumothorax recurred, and high-resolution computed tomography revealed multiple cystic, cavitary and nodular lesions.
  • After the operation, the patient received chemotherapy; no recurrence of pneumothorax was found during 6 months of follow-up.

  • MedlinePlus Health Information. consumer health - Collapsed Lung.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16520841.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


Advertisement
4. Ettl T, Kleinheinz J, Mehrotra R, Schwarz S, Reichert TE, Driemel O: Infraorbital cutaneous angiosarcoma: a diagnostic and therapeutic dilemma. Head Face Med; 2008;4:18
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infraorbital cutaneous angiosarcoma: a diagnostic and therapeutic dilemma.
  • BACKGROUND: A cutaneous angiosarcoma is a rare malignant tumour of vascular endothelial cells with aggressive clinical behaviour and poor prognosis.
  • CASE PRESENTATION: This case presents a 64-year-old man with a six-month-history of a recurrent diffuse and erythematous painless swelling below the left eye.
  • Histopathologic examination of the specimen diagnosed a cutaneous angiosarcoma.
  • Neither, finally achieved negative margins on permanent sections, nor a following chemotherapy could prevent the recurrence of the disease after five months and the patient's dead 21 months after the first diagnosis.
  • CONCLUSION: The case elucidates the current diagnostic and therapeutic dilemma of this entity, which shows an unfavourable clinical course in spite of multimodal therapy.
  • [MeSH-major] Facial Neoplasms / pathology. Hemangiosarcoma / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Fatal Outcome. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 Nov 15;98(10):2251-6 [14601096.001]
  • [Cites] J Am Acad Dermatol. 2004 Jun;50(6):867-74 [15153886.001]
  • [Cites] Cancer. 1987 Mar 1;59(5):1046-57 [3815265.001]
  • [Cites] Am J Surg. 1990 Oct;160(4):365-9 [2221235.001]
  • [Cites] Am J Surg. 1994 Nov;168(5):451-4 [7977971.001]
  • [Cites] Cancer. 1995 Jul 15;76(2):319-27 [8625109.001]
  • [Cites] Cancer. 2003 Oct 15;98(8):1716-26 [14534889.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):361-6 [15948172.001]
  • [Cites] Am J Clin Oncol. 2006 Oct;29(5):524-8 [17023791.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):2034-7 [10570428.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1061-6 [11474291.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2003 Sep;17(5):594-5 [12941106.001]
  • [Cites] J Am Acad Dermatol. 2003 Sep;49(3):530-1 [12963925.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2005 May;19(3):357-9 [15857466.001]
  • (PMID = 18694495.001).
  • [ISSN] 1746-160X
  • [Journal-full-title] Head & face medicine
  • [ISO-abbreviation] Head Face Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2533304
  •  go-up   go-down


5. Thong PS, Ong KW, Goh NS, Kho KW, Manivasager V, Bhuvaneswari R, Olivo M, Soo KC: Photodynamic-therapy-activated immune response against distant untreated tumours in recurrent angiosarcoma. Lancet Oncol; 2007 Oct;8(10):950-2
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic-therapy-activated immune response against distant untreated tumours in recurrent angiosarcoma.
  • [MeSH-major] Head and Neck Neoplasms / drug therapy. Hemangiosarcoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Photochemotherapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17913664.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, Takimoto CH, Kraft AS, Elias AD, Brockstein B, Blachère NE, Edgar MA, Schwartz LH, Qin LX, Antonescu CR, Schwartz GK: Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol; 2009 Jul 01;27(19):3133-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.
  • PURPOSE Since activity of sorafenib was observed in sarcoma patients in a phase I study, we performed a multicenter phase II study of daily oral sorafenib in patients with recurrent or metastatic sarcoma.
  • In each arm, 12 patients who received 0 to 1 prior lines of therapy were treated (0 to 3 for angiosarcoma and malignant peripheral-nerve sheath tumor).
  • Five of 37 patients with angiosarcoma had a partial response (response rate, 14%).
  • There was no correlation between phosphorylated extracellular signal regulated kinase expression and response in six patients with angiosarcoma with paired pre- and post-therapy biopsies.
  • CONCLUSION As a single agent, sorafenib has activity against angiosarcoma and minimal activity against other sarcomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Pyridines / therapeutic use. Sarcoma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Nov 15;86(10):2034-7 [10570428.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Oct;47(10):853-9 [18615679.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2824-31 [12065559.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17):3586-91 [12202658.001]
  • [Cites] Int J Cancer. 2002 Aug 20;100(6):623-6 [12209598.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1706-12 [15117993.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34 [15451219.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Mol Cell Biol. 1994 Jan;14(1):641-5 [8264632.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Dec;78(2):138-44 [7828144.001]
  • [Cites] J Biol Chem. 1995 Dec 1;270(48):28834-8 [7499408.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):866-73 [15681532.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):965-72 [15613696.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):361-6 [15948172.001]
  • [Cites] Cancer J. 2005 May-Jun;11(3):241-7 [16053668.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):706-11 [16496406.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2023-9 [17404082.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2643-50 [17473195.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2755-63 [17602081.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7106-12 [17671177.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):361-7 [18202410.001]
  • [Cites] Curr Treat Options Oncol. 2007 Dec;8(6):428-34 [18066504.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):821-2 [18296418.001]
  • [Cites] Mol Cancer Ther. 2008 Apr;7(4):890-6 [18413802.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2717-25 [18451237.001]
  • [Cites] Gynecol Oncol. 2008 Jun;109(3):323-8 [18394689.001]
  • [Cites] Gynecol Oncol. 2008 Jun;109(3):329-34 [18534250.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):543-9 [11872347.001]
  • (PMID = 19451436.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / N01CM62202; United States / NCI NIH HHS / CA / P01 CA047179
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  • [Other-IDs] NLM/ PMC2716936
  •  go-up   go-down


7. Jha S, Chan KK, Poole CJ, Rollason TP: Pregnancy following recurrent angiosarcoma of the ovary--a case report and review of literature. Gynecol Oncol; 2005 Jun;97(3):935-7
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pregnancy following recurrent angiosarcoma of the ovary--a case report and review of literature.
  • Surgery and radiotherapy have been the traditional treatment modalities.
  • CASE: The case we present is the only reported long-term survivor of recurrent ovarian angiosarcoma.
  • Her initial treatment was surgical, both at presentation and relapse but since she wished conservation of fertility, radical surgery and radiotherapy were avoided and she underwent further adjuvant chemotherapy with doxorubicin and ifosfamide.
  • She remains in remission 6 years after treatment of recurrence of the primary tumor and has had a successful pregnancy following treatment.
  • CONCLUSION: Adjuvant chemotherapy of ovarian angiosarcoma with a combination of doxorubicin and ifosfamide appears effective and should be considered in women at risk of relapse who wish to conserve fertility.
  • [MeSH-major] Hemangiosarcoma / therapy. Neoplasm Recurrence, Local. Ovarian Neoplasms / therapy. Pregnancy Complications, Neoplastic
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Fertility. Humans. Ifosfamide / administration & dosage. Pregnancy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943995.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 15
  •  go-up   go-down


8. Afonso PV, Antunes MJ: Primary cardiac angiosarcoma. Extended resection of the right atrial wall. Case report. Rev Port Cardiol; 2007 Nov;26(11):1189-94

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cardiac angiosarcoma. Extended resection of the right atrial wall. Case report.
  • We report the case of a 51-year-old patient who presented with tiredness and leg swelling, with recurrent pericardial effusion; a right atrial tumor, suggestive of sarcoma, was diagnosed, which responded poorly to chemotherapy.
  • Two months after surgery she had a new recurrence of pericardial effusion and chemotherapy was reinitiated.
  • [MeSH-major] Heart Neoplasms / surgery. Hemangiosarcoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18297840.001).
  • [ISSN] 0870-2551
  • [Journal-full-title] Revista portuguesa de cardiologia : orgão oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology
  • [ISO-abbreviation] Rev Port Cardiol
  • [Language] eng; por
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


9. Isa NM, James DT, Saw TH, Pennisi R, Gough I: Primary angiosarcoma of the thyroid gland with recurrence diagnosed by fine needle aspiration: a case report. Diagn Cytopathol; 2009 Jun;37(6):427-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary angiosarcoma of the thyroid gland with recurrence diagnosed by fine needle aspiration: a case report.
  • Angiosarcoma of the thyroid is a rare and aggressive primary malignant tumor of the thyroid originally reported in patients from the Swiss Alpine region.
  • We describe a case of primary angiosarcoma of the thyroid in a 48-year-old female, who presented with a rapidly enlarging neck mass associated with compressive symptoms.
  • A diagnosis of poorly differentiated malignant tumor consistent with angiosarcoma was made.
  • The patient was treated with radiation therapy but developed recurrence of the tumor.
  • Second aspiration cytology of the recurrent tumor yielded hypocellular smears containing singularly dispersed atypical cells having eccentrically-placed nuclei with prominent macronucleoli and intracytoplasmic vacuoles within a background of inflammatory cells, consistent with recurrent angiosarcoma.
  • Chemotherapy was started but she succumbed to the disease 7 months after diagnosis.
  • [MeSH-major] Hemangiosarcoma / diagnosis. Hemangiosarcoma / pathology. Thyroid Gland / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19306411.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31
  •  go-up   go-down


10. Lahat G, Dhuka AR, Lahat S, Smith KD, Pollock RE, Hunt KK, Ravi V, Lazar AJ, Lev D: Outcome of locally recurrent and metastatic angiosarcoma. Ann Surg Oncol; 2009 Sep;16(9):2502-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of locally recurrent and metastatic angiosarcoma.
  • BACKGROUND: Angiosarcoma (AS) is a rare soft tissue sarcoma with an enhanced propensity for local and systemic failure.
  • The outcome of locally recurrent and metastatic AS treated at a single institution was evaluated.
  • RESULTS: Forty-four patients were treated for locally recurrent AS; the majority (59%) were <or=5 cm; the most common sites were skin (48%) and breast (32%).
  • Thirty-two patients (73%) had surgery; 73% received chemotherapy; radiation was delivered to 41%.
  • Multivariable analysis identified size >5 cm as the only independent adverse prognosticator of recurrent AS-specific survival [hazard ratio (HR): 3.26, P = 0.04].
  • Chemotherapy, mainly doxorubicin- and/or paclitaxel-based regimens, were administered to 95 patients (96%).
  • CONCLUSION: Locally recurrent AS is often treatable; complete resection can potentially prolong survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hemangiosarcoma / secondary. Neoplasm Recurrence, Local / pathology. Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19551444.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. O'Callaghan DS, Breen DP, Young V: Angiosarcoma of the right atrium masquerading as recurrent pulmonary embolism. Thorac Cardiovasc Surg; 2008 Dec;56(8):488-90
MedlinePlus Health Information. consumer health - Pulmonary Embolism.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiosarcoma of the right atrium masquerading as recurrent pulmonary embolism.
  • Primary cardiac angiosarcoma is a rare tumor that may present with features mimicking venous thromboembolic disease, making the diagnosis particularly challenging.
  • As a result, the outlook for most patients remains dismal even with aggressive multimodality treatment.
  • We report a case of angiosarcoma masquerading as recurrent pulmonary embolism successfully treated by radical surgery and adjuvant cytotoxic chemotherapy.
  • [MeSH-major] Heart Neoplasms / diagnosis. Hemangiosarcoma / diagnosis. Pulmonary Embolism / diagnosis

  • Genetic Alliance. consumer health - Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19012217.001).
  • [ISSN] 0171-6425
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Thong PS, Olivo M, Kho KW, Bhuvaneswari R, Chin WW, Ong KW, Soo KC: Immune response against angiosarcoma following lower fluence rate clinical photodynamic therapy. J Environ Pathol Toxicol Oncol; 2008;27(1):35-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune response against angiosarcoma following lower fluence rate clinical photodynamic therapy.
  • Tumor response to photodynamic therapy (PDT) is dependent on treatment parameters used.
  • In particular, the light fluence rate may be an important determinant of the treatment outcome.
  • In this clinical case report, we describe the response of angiosarcoma to PDT carried out using different fluence rates and drug and light doses.
  • A patient with recurrent multifocal angiosarcoma of the head and neck was recruited for PDT.
  • Repeat PDT carried out on a recurrent lesion at a lower fluence rate resulted in eradication of both treated and untreated lesions despite the lower total light dose delivered.
  • Our clinical observations show that lower fluence rate PDT results in better outcome and also indicate that the fluence rate, rather than the total light dose, is a more crucial determinant of the treatment outcome.
  • [MeSH-major] Head and Neck Neoplasms / drug therapy. Hemangiosarcoma / drug therapy. Neoplasm Recurrence, Local. Photochemotherapy / methods. Skin Neoplasms / drug therapy
  • [MeSH-minor] Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Humans. Immunity, Cellular / drug effects. Immunity, Cellular / radiation effects. Lasers. Male. Middle Aged. Photosensitizing Agents / administration & dosage. Photosensitizing Agents / therapeutic use. Povidone. Protoporphyrins / administration & dosage. Protoporphyrins / therapeutic use

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. POLYVINYLPYRROLIDONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18551894.001).
  • [ISSN] 0731-8898
  • [Journal-full-title] Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  • [ISO-abbreviation] J. Environ. Pathol. Toxicol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photolon; 0 / Photosensitizing Agents; 0 / Protoporphyrins; 9003-39-8 / Povidone
  •  go-up   go-down


13. Pink D, Rahm J, Schoeler D, Schoenknecht TM, Reichardt P: Activity of paclitaxel in radiation induced and other secondary angiosarcomas. J Clin Oncol; 2009 May 20;27(15_suppl):10578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 10578 Background: Angiosarcomas (AS) represent 1-2% of adult soft tissue sarcomas and can arise anywhere in the body.
  • Major predisposing factors are therapeutic radiation and chronic lymphedema.
  • We report on a retrospectice single center experience with chemotherapy in 17 patients (pts.) with secondary angiosarcomas (SAS).
  • 12 female patients suffered from angiosarcoma of the breast/thoracic wall following operation and radiation + chemotherapy of a primary breast cancer with an interval of a median of 6 years (range 2-15 years).
  • 1 patient developed a SAS 6 years after resection and radiation of a liposarcoma in the limb.
  • RESULTS: 14/17 pts. received surgery as first treatment for SAS.
  • 10 pts. developed a locoregional recurrence, 1 pt. distant metastases.
  • All 14 patients with recurrent/metastatic disease were treated with chemotherapy.
  • 12 pts. received paclitaxel at a dose of 175 mg/m<sup>2</sup> q3w or 50-70 mg/m<sup>2</sup> q1w as first- or second-line therapy.
  • In only 3/11 cases, pts. responded to Anthracycline-based chemotherapy.
  • CONCLUSIONS: Paclitaxel shows high activity in SAS, comparable to the results in face and scalp angiosarcomas and can be considered a standard treatment option.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963758.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Quan ML, Delgado R, Van Zee K: Atypical vascular lesions including angiosarcoma after breast conservation. J Clin Oncol; 2004 Jul 15;22(14_suppl):689

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical vascular lesions including angiosarcoma after breast conservation.
  • : 689 Background: The development of angiosarcom (AS) after breast conservation and radiotherapy (BCT) is a rare complication of breast cancer (BC) treatment carrying a poor prognosis.
  • BC and AVP or AS treatment details were recorded and vascular lesion pathology reviewed.
  • Fifty-five percent (10/18) had adjuvant chemotherapy and 69% (9/13) took tamoxifen after BCT.
  • Median time to diagnosis of AS post BC diagnosis was 81 mos (38-137) and 76 mos (54-63) for AVP.
  • Treatment of AS was wide local excision (WLE) in 2 patients; both are NED.
  • 23% (3/13) of these women had additional chemotherapy and 7.7 % had adjuvant RT.
  • Treatment of AVP was TM in 1 patient followed by chemotherapy, she is NED.
  • Of these, one developed recurrent AVP 1 year later.
  • CONCLUSIONS: Post BCT AS has a grave prognosis in spite of multimodality therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016965.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Bacchi CE, Silva TR, Zambrano E, Plaza J, Suster S, Luzar B, Lamovec J, Pizzolitto S, Falconieri G: Epithelioid angiosarcoma of the skin: a study of 18 cases with emphasis on its clinicopathologic spectrum and unusual morphologic features. Am J Surg Pathol; 2010 Sep;34(9):1334-43
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid angiosarcoma of the skin: a study of 18 cases with emphasis on its clinicopathologic spectrum and unusual morphologic features.
  • We report 18 cases of cutaneous angiosarcoma with predominant or exclusive epithelioid morphology.
  • Therapeutic modalities included combined local excision, chemotherapy, and radiotherapy, depending on patient clinical status.
  • Of the 9 patients available for follow-up, 5 were alive and apparently well, 2 had recurrent disease, and 2 had died of tumor.
  • Our data show that epithelioid cutaneous angiosarcoma may have a broad morphological spectrum, raising interpretive challenges on microscopy.
  • [MeSH-major] Epithelioid Cells / pathology. Hemangiosarcoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20697249.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


16. Miura K, Kum Y, Han G, Tsutsui Y: Radiation-induced laryngeal angiosarcoma after cervical tuberculosis and squamous cell carcinoma: case report and review of the literature. Pathol Int; 2003 Oct;53(10):710-5
Genetic Alliance. consumer health - Tuberculosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced laryngeal angiosarcoma after cervical tuberculosis and squamous cell carcinoma: case report and review of the literature.
  • Primary laryngeal angiosarcoma (LA) is quite rare with only 13 cases reported in English literature to date.
  • A case of LA after radiation therapy for tuberculosis and squamous cell carcinoma is reported.
  • A 70-year-old woman had a history of radiation therapy for left cervical tuberculosis at the age of 28.
  • At 60 years of age a squamous cell carcinoma of the larynx was found and chemotherapy and radiotherapy, consisting of a total dose of 68.4 Gy, were administered.
  • At the age of 68, recurrent squamous cell carcinoma was suspected from several biopsies, and a total laryngectomy with right thyroidectomy was performed.
  • In the present case, it was suspected that irradiation to the larynx for cervical tuberculosis and squamous cell carcinoma induced angiosarcoma.
  • The patient was still alive despite multiple skin and soft tissue metastasis 3 years and 6 months after the radical operation.
  • Distinction of postirradiation angiosarcoma from pseudoangiosarcomatous carcinoma seems difficult but is important because irradiation is not effective and an initial radical surgery is the only effective treatment.
  • Although irradiation is a common treatment for laryngeal squamous cell carcinoma, this is only the second case of radiation-induced LA in English literature.
  • [MeSH-major] Carcinoma, Squamous Cell / etiology. Hemangiosarcoma / etiology. Laryngeal Neoplasms / etiology. Neoplasms, Multiple Primary / etiology. Neoplasms, Radiation-Induced / etiology. Tuberculosis, Lymph Node / radiotherapy
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Laryngectomy. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14516323.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  • [Number-of-references] 30
  •  go-up   go-down


17. Valbuena JR, Levenback C, Mansfield P, Liu J: Angiosarcoma of the spleen clinically presenting as metastatic ovarian cancer. A case report and review of the literature. Ann Diagn Pathol; 2005 Oct;9(5):289-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiosarcoma of the spleen clinically presenting as metastatic ovarian cancer. A case report and review of the literature.
  • We report a case of the 43-year-old woman with a long-standing history of recurrent ovarian carcinoma treated with surgery and multiple courses of radiation therapy and chemotherapy who clinically appeared to have a metastatic ovarian cancer to the spleen and treated with partial resection of stomach and splenectomy.
  • However, histopathologic examination of the specimen showed the tumor to be of a primary angiosarcoma.
  • [MeSH-major] Hemangiosarcoma / pathology. Neoplasms, Second Primary / pathology. Ovarian Neoplasms / pathology. Splenic Neoplasms / pathology


18. Suppiah R, Wood L, Elson P, Budd GT: Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS). Invest New Drugs; 2006 Nov;24(6):509-14
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS).
  • METHODS: Patients with advanced, recurrent, or metastatic STS, without prior chemotherapy, were enrolled in a dose escalation trial.
  • HISTOLOGY: leiomyosarcoma 10, spindle cell sarcoma 3, synovial sarcoma 2, angiosarcoma 1, fibrous histiocytoma 1, epitheliod hemangio-endothelioma 1, and 3 not specified.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 1995 Oct;20(3):193-201 [8748009.001]
  • [Cites] Cancer. 1981 May 15;47(10):2422-9 [7272896.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1600-8 [7541449.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Clin Ter. 1998 Mar-Apr;149(2):121-5 [9780476.001]
  • [Cites] Cancer. 1982 Dec 15;50(12):2757-62 [7139566.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):150-7 [10458228.001]
  • [Cites] Ann Oncol. 1999 Sep;10(9):1087-94 [10572607.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1276-85 [8315425.001]
  • [Cites] Ann Oncol. 2001 Sep;12(9):1281-8 [11697841.001]
  • [Cites] J Clin Oncol. 1987 Jun;5(6):840-50 [3585441.001]
  • [Cites] Eur J Cancer. 2002 Dec;38(18):2397-406 [12460784.001]
  • [Cites] Cancer. 1984 May 1;53(9):1825-32 [6367947.001]
  • [Cites] Am J Clin Oncol. 1996 Dec;19(6):574-6 [8931674.001]
  • [Cites] Cancer. 1994 May 15;73(10):2506-11 [8174046.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2081-6 [10811673.001]
  • [Cites] Ann Oncol. 1994 Jul;5(6):539-42 [7918126.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):15-21 [8418226.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1706-12 [15117993.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1269-75 [8315424.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2824-31 [12065559.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2378-84 [9196153.001]
  • (PMID = 16791410.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Taxoids; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


19. Blanchard DK, Reynolds CA, Grant CS, Donohue JH: Primary nonphylloides breast sarcomas. Am J Surg; 2003 Oct;186(4):359-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to examine the presentation, treatment, and prognosis of patients presenting with these neoplasms.
  • RESULTS: Of the 55 patients, 17 had breast-conserving therapy and 38 women had mastectomy.
  • The types of sarcoma included angiosarcoma (18), malignant fibrous histiocytoma (11), stromal sarcoma (8), liposarcoma (4), leiomyosarcoma (4), dermatofibrosarcoma protuberans (4), osteosarcoma (3), fibrosarcoma (2), and rhabdomyosarcoma (1).
  • Twenty-nine of 53 patients (55%) developed recurrent sarcoma, and 23 patients (43%) died of their disease.
  • Patients with angiosarcoma had a poorer outcome than other sarcoma patients.
  • Twelve of 18 patients (67%) died of angiosarcoma, compared with 11 of 32 patients (34%) of all other sarcoma patients combined.
  • Of 34 patients who did not receive adjuvant chemotherapy or radiation, 13 died of their disease (38%), as compared with 10 of 16 patients (63%) who did receive adjuvant therapy.
  • CONCLUSIONS: While primary nonphylloides breast sarcomas are rare tumors, their treatment and prognosis are poor.
  • Adjuvant chemotherapy and radiation did not improve survival in this report.
  • Surgical extirpation remains the only effective treatment.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14553850.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Bousquet G, Confavreux C, Magné N, de Lara CT, Poortmans P, Senkus E, de Lafontan B, Bolla M, Largillier R, Lagneau E, Kadish S, Lemanski C, Ozsahin M, Belkacémi Y: Outcome and prognostic factors in breast sarcoma: a multicenter study from the rare cancer network. Radiother Oncol; 2007 Dec;85(3):355-61
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While surgical resection is the primary treatment, the role of radiation therapy (RT) and chemotherapy remains unclear.
  • This study aimed at defining prognostic factors and treatment strategies.
  • A total dose of 50 Gy in 25 fractions was delivered in 50 patients.
  • At the completion of treatment, 89 patients had no residual tumour.
  • RESULTS: After a median follow-up of 64 months, 56 patients developed recurrent disease: 38 presented a local relapse and 37 developed distant metastases.
  • In multivariate analysis, favourable prognostic factors for better local control were: no residual tumour after treatment, no cellular pleomorphism, and histology other than angiosarcoma.
  • For DFS, the five favourable prognostic factors were non-menopausal status, no residual tumour after treatment, non-angiosarcoma histology, absence of tumour necrosis, and grade 1-2 histology.
  • CONCLUSION: While angiosarcoma has the worst prognosis, the outcome of the other types of sarcomas may be worsened by residual tumour after loco-regional treatment and high grade histology, a classical prognostic factor of the other soft tissue sarcomas.
  • During surgical procedure axillary dissection is not mandatory.
  • [MeSH-major] Breast Neoplasms / therapy. Hemangiosarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Middle Aged. Prognosis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18023492.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Ireland
  •  go-up   go-down


21. Lejeune FJ, Pujol N, Liénard D, Mosimann F, Raffoul W, Genton A, Guillou L, Landry M, Chassot PG, Chiolero R, Bischof-Delaloye A, Leyvraz S, Mirimanoff RO, Bejkos D, Leyvraz PF: Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol; 2000 Nov;26(7):669-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
  • AIMS: Patients with non-resectable soft tissue sarcomas of the extremities do not live longer if they are treated by amputation or disarticulation.
  • In order to avoid major amputations, we tested isolated limb perfusion (ILP) with tumour necrosis factor alpha (TNF)+melphalan+/-interferon-gamma (IFN) as a pre-operative, neoadjuvant limb salvage treatment.
  • Thirteen cases were recurrent or progressive after previous therapy; five tumours had a diameter >/=20 cm, and four were multiple or regionally metastatic.
  • There were six malignant fibrous histiocytomas, five liposarcomas, four malignant peripheral nerve sheath tumours, three rhabdomyosarcomas, two leiomyosarcomas, one recurrent extraskeletal osteosarcoma and one angiosarcoma.
  • All patients had fever for 24 hours but only one developed a reversible grade 3 distributive shock syndrome with no sequelae.
  • Seventeen patients (77%) underwent limb-sparing resection of the tumour remnants after a median time of 3.4 months: 10 resections were intracompartmental and seven extracompartmental.
  • Adjuvant chemotherapy was given to eight patients and radiotherapy to six.
  • The median disease free and overall survival times have been >12.5 and 18.7 months respectively: this is similar to the outcome after primary amputations for similar cases.
  • CONCLUSION: ILP with TNF and chemotherapy is an efficient limb sparing neoadjuvant therapy for a priori non-resectable limb soft tissue sarcomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leg / surgery. Sarcoma / drug therapy. Sarcoma / surgery. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Chemotherapy, Cancer, Regional Perfusion. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Interferon-gamma / administration & dosage. Interferon-gamma / adverse effects. Male. Melphalan / administration & dosage. Melphalan / adverse effects. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local / surgery. Radiotherapy, Adjuvant. Salvage Therapy. Survival Analysis. Tumor Necrosis Factor-alpha / administration & dosage. Tumor Necrosis Factor-alpha / adverse effects

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Harcourt Publishers Ltd.
  • (PMID = 11078614.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 80168379AG / Doxorubicin; 82115-62-6 / Interferon-gamma; Q41OR9510P / Melphalan; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


22. Pruthi S, Reynolds C, Johnson RE, Gisvold JJ: Tamoxifen in the management of pseudoangiomatous stromal hyperplasia. Breast J; 2001 Nov-Dec;7(6):434-9
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To confirm the diagnosis, a biopsy is required primarily to distinguish PASH from a low-grade angiosarcoma.
  • The management of the palpable mass and associated symptoms has included excisional biopsy, often leading to recurrent excisions and even mastectomy.
  • [MeSH-major] Angiomatosis / drug therapy. Angiomatosis / pathology. Antineoplastic Agents, Hormonal / therapeutic use. Breast Diseases / drug therapy. Breast Diseases / pathology. Tamoxifen / therapeutic use

  • Genetic Alliance. consumer health - Pseudoangiomatous stromal hyperplasia.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Breast J. 2003 Jul-Aug;9(4):344 [12846880.001]
  • (PMID = 11843858.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


23. Srivastava A, Nielsen PG, Dal Cin P, Rosenberg AE: Monophasic synovial sarcoma of the liver. Arch Pathol Lab Med; 2005 Aug;129(8):1047-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A right partial hepatectomy was performed with a preoperative differential diagnosis of angiosarcoma versus hepatocellular carcinoma.
  • Postoperative clinical evaluation of the extremities and a positron emission tomographic scan performed 4 weeks after surgery showed no evidence of recurrent or metastatic disease.
  • The patient was started on an aggressive 4-drug chemotherapy regimen, but died 3 months thereafter from widespread metastatic disease.
  • [MeSH-minor] Carcinoma, Hepatocellular / diagnosis. Chemotherapy, Adjuvant. Chromosomes, Human, Pair 18. Chromosomes, Human, X. Diagnosis, Differential. Fatal Outcome. Female. Genetic Markers. Hemangiosarcoma / diagnosis. Hepatectomy. Humans. Middle Aged. Translocation, Genetic

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16048399.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down






Advertisement